Contamination and health risk assessment of heavy metals in beach sediments of Red Sea and Gulf of Aqaba, Egypt.

The Egyptian beaches on the Red Sea and the Gulf of Aqaba in Sinai are a destination for international tourism throughout the year. Therefore, assessing the concentration levels of heavy metal pollutants and identifying the extent of their impact on human health is important. Single and integrated pollutants indices have been used to assess the risks of these elements. The results of single indices proved that the study area contain Fe and Zn came mostly from natural source while Cu, Pb, Cd and Hg originated from anthropogenic sources. However, the integrated pollutants indices revealed that this area is not polluted with heavy metals. On the other hand, the hazard index, and the carcinogenic risk over the lifetime coefficients proved that the beach sand of the study area is completely safe and does not have additional health risks to children or adults, where LCR < 10-6.

Development of hybrid spectrofluorimetric method for simultaneous determination of Valsartan and Sacubitril in LCZ696 tablets.

A hybrid Spectrofluorimetric method was developed for the simultaneous determination of binary mixtures, without prior separation steps. It coupled synchronous spectrofluorimetry with derivative ratio mathematical treatment. The method was applied successfully to quantify a new model binary mixture consisting of Valsartan (VAL) and Sacubitril (SAC). This mixture was recently approved by FDA as LCZ696. It added a great value in reducing morbidity and mortality in resistant heart failure (HF) patients. First derivative ratio synchronous fluorescence was measured at 258-295 (peak-to-peak) and 204 nm for VAL and SAC, respectively. ICH guidelines were fulfilled for the method validation. VAL and SAC showed linear responses in the range of 60-200 and 20-200 ng mL-1, respectively. The proposed method was compared, in details, with the reported ones. Its high accuracy, selectivity, simplicity and affordable cost recommend method application in large-scale routine analysis of LCZ696 tablets. Moreover, reliable application of this new integrated spectrofluorimetric method suggests expansion of its application for various therapeutic combinations and different matrices.

Gradient HPLC-DAD method for quantification of novel oral anticoagulant "Edoxaban" in plasma: Its selective determination in presence of sixteen co-administered drugs.

As an anticoagulant, Edoxaban (EDX) is a high risk drug that may cause a life-threatening bleeding. Also, it is prescribed as a chronic therapy for atrial fibrillation and venous thromboembolism patients. They are special population that needs appropriate care and optimum dosing of EDX. Hence, its monitoring in the patient plasma is fundamental, especially in emergency and special circumstances. However, such patient mostly receives many drugs of different pharmacological classes, side by side with EDX. This study represents the first attempt to quantify EDX in plasma without interference of the plasma matrix or concomitant medications. An accurate RP-HPLC-DAD method was developed for this purpose. It succeeded to monitor EDX level, selectively, without interference of plasma matrix or 16 of its frequently co-administered drugs. All drugs were extracted from plasma samples by protein precipitation followed by evaporation and concentration. EDX was well resolved from the co-administered drugs on C8 column using linear gradient elution of methanol and phosphate buffer (pH 4), at a flow rate of 1 mL/min. EDX appeared at retention time 9.6 min and was quantified at its λmax (290 nm). It exhibited a linear response over the concentration range of 0.15-2.2 µg/mL plasma which covers the reported therapeutic concentration. The suggested method fulfilled the US FDA guidelines for bioanalytical method validation. The developed method is fully discussed in comparison with the reported techniques. An in vivo study was performed to ensure applicability of the method on real plasma samples without interference from plasma matrix, co-administered drugs or the expected metabolites. It presented a unique selectivity of the method that guarantees accurate laboratory monitoring of EDX in plasma in almost all combined treatments including such novel oral anticoagulant drug.

Serum metastasin mRNA is an important survival predictor in breast cancer.

This study investigates the possible prognostic role of serum metastasin messenger RNA (mRNA) in breast carcinoma as a non-invasive screening tool, and determines metastasin mRNA in the serum of breast cancer patients with high sensitivity (85%) and specificity (100%). A significant difference (P = 0.05) was observed between serum metastasin mRNA and the number of involved lymph nodes. Patients with higher expression of serum metastasin showed poor survival (six times worse) than those with lower levels. Patients negative for serum metastasin mRNA suffered recurrences, while those positive for serum metastasin mRNA suffered distant metastases. The results of this study suggest that serum metastasin mRNA represents an important survival marker in breast carcinoma.

Chemical composition of Egyptian and UAE propolis.

The chemical composition of propolis samples obtained from Behera, Egypt and Dubai, UAE, have been investigated by GC-MS and thirty four compounds have been tentatively identified. Some of these compounds have not been reported previously in Egyptian propolis from different regions. The Egyptian sample contains a high amount of aliphatic (13.7%) and aromatic (14.4%) acids. The alcohols, phenols and esters account for about 17.0% of the total content analysed. Some anthraquinone and flavone derivatives have also been detected (10%). The UAE sample is characterised by the presence of a high content of aliphatic acids (15.2%) and a low content of aromatic acids (4.3%). The aldehydes, alcohols, phenols and esters amount to about 9%. In addition to these some other compounds (high molecular weight alkanes, sugar derivatives, anthraquinone derivatives and flavone derivatives) are also present to the extent of about 33%.

Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.

OBJECTIVES: To compare the clinical and hormonal effects of finasteride and a combination regimen of cyproterone acetate (CPA) plus ethinyl estradiol (EE2) in the treatment of hirsutism. METHODS: Forty hirsute women were enrolled in a prospective randomized trial. Twenty-nine had polycystic ovary syndrome (PCOS) and 11 had idiopathic hirsutism. Patients were randomly treated with finasteride (5 mg/day; n=20) or CPA plus EE2 [CPA (25 mg/day on days 5-14) plus EE2 (20 microg/day on days 5-25) n=20] for 9 months. Main outcome measurement was a reduction in hair growth. Hirsutism score and hormone levels were measured at the beginning and at the end of the study. The student t-test and Mann-Whitney U tests were used for analysis of the data. RESULTS: The modified Ferriman-Gallwey scores for hirsutism decreased significantly at the end of the study from a mean+/-SD of 23.7+/-4.4 to 11.3+/-1.5; P=<0.001 in finasteride group and from 22.3+/-4.2 to 11.4+/-1.2; P=<0.001 in CPA plus EE2 group. Improvement of hirsutism induced by the two treatment methods was similar (47.6 % vs. 51.1%; P=0.2). Treatment with CPA plus EE2 significantly decreased serum total and free T, A, DHEAS, and DHT and increased SHBG levels. Finasteride significantly increased total T but reduced DHT levels. CONCLUSION: Finasteride and CPA plus EE2 are equally effective in decreasing hirsutism, despite significantly different effects on serum hormone levels.